Tag Archive for: astrazeneca

Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points

/in

Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors Barcelona, […]

Read more

DaltonTx raises £4 million seed financing to build the intelligence backbone of drug discovery

/in

DaltonTx, a UK-based technology company, today announces its exit from from stealth and the completion of a £4 million seed financing round to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D so breakthrough medicines reach patients faster. AI offers pharma a unique opportunity to discover medicines more effectively and […]

Read more

Will Trump hit foreign pharma companies with tariffs?

/in

Well, the last fortnight’s certainly been a rollercoaster. Ever since President Trump announced his plans for sweeping tariffs on foreign goods entering the US on Thursday April 3, markets have hardly been able to catch their collective breath. First there was the initial shock, at which point stocks tanked, before lurching up and down, and […]

Read more

Hot topic: Doubts over UK’s growth potential as AstraZeneca axes vaccine plant

/in

Just a week after science minister Lord Vallance was appointed the “Oxford-Cambridge Innovation Champion”, the gloss has well and truly disappeared from the government’s attempts to bolster its life sciences credentials. Just as the Labour government was looking for a good news story to highlight the UK’s potential as a site for international investment, the […]

Read more

From $1bn deals to Smart RNA – read our news roundup

/in

AstraZeneca buys Novo Holdings portfolio company Amolyt in potential $1bn+ deal Novo Holdings A/S and Sofinnova Partners, two leading life sciences investors, made headlines on Thursday when portfolio company Amolyt Pharma entered into a definitive agreement to be acquired by AstraZeneca at a purchase price of US$800 million upfront and a potential milestone payment of […]

Read more